Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227412 | 1.00 | EGFR (0.60) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL7226007 | 1.00 | EGFR (0.60) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL7226011 | 1.00 | EGFR (0.60) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL7224748 | 0.92 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL1386469 | 0.92 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL7224798 | 0.87 | EGFR (0.70) | EGFRERBB2 | |
| SCHEMBL7227388 | 0.87 | KDR (0.55) | EGFRERBB2RET | |
| SCHEMBL7226004 | 0.87 | KDR (0.55) | EGFRERBB2RET | |
| SCHEMBL7227393 | 0.87 | KDR (0.55) | EGFRERBB2RET | |
| SCHEMBL6993114 | 0.87 | KDR (0.55) | EGFRERBB2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | EGFR 137/4885ERBB2 25/4885ABL1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.